Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is :

- To determine the maximum tolerated dose (MTD) for PEP005 Topical Gel in patients with actinic keratoses.

- To evaluate patients for clinical safety

- To determine the systemic absorption of PEP005 Topical Gel


Clinical Trial Description

Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.

This is an open label, dose escalation, cohort study to determine the maximum tolerated dose (MTD) of PEP005 Topical Gel, administered once daily for two consecutive days (90 ul gel applied topically over a 3 x 3cm template surrounding a target lesion), to patients with actinic keratoses (AK). The study will be conducted in one centre in the US. Three patients will be entered initially at the lowest dose level (0.01%) with up to an additional three patients to be entered in the event of a dose limiting toxicity (DLT) in the initial patients. DLT are defined as 'severe' local skin reactions observed by the Investigator, either prior to treatment on Day 2 ( following treatment on Day 1 ) or observed on Day 8 (following treatment on Day 2). Based on findings from phase I studies and the low systemic absorption found in non-clinical toxicokinetic evaluations, no systemic toxicity is anticipated.Once determined A total of 10 patients will be treated at the MTD in order to confirm it's determination. Based on findings from the phase I study, the starting dose will be 0.01% PEP005 Gel.

Secondary objectives of the study are (1) evaluate the clinical efficiency of PEP005 Topical Gel, when administered once daily for two consecutive days and (2) determine the systemic absorption of PEP005 Topical Gel at the MTD . Hematologic and biochemical assessments will be undertaken at the screening visit and at days 8 and 29 . Adverse events will be assessed at every study visit. Clinical response to treatment will be assessed at Days 8, 15 and 29. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00239135
Study type Interventional
Source Peplin
Contact
Status Completed
Phase Phase 2
Start date September 2005
Completion date December 2005

See also
  Status Clinical Trial Phase
Recruiting NCT06206681 - Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
Completed NCT00115154 - Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Phase 4
Recruiting NCT04336514 - A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures N/A
Completed NCT00116649 - Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Phase 4
Recruiting NCT05942794 - Identification of Oral Lesions Through an Autofluorescence System N/A
Withdrawn NCT02851693 - Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection N/A
Withdrawn NCT02813902 - A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors Phase 1
Completed NCT00121511 - The Effect of Efudex Treatment on Photoaged Skin N/A
Completed NCT00114023 - 1-Year Follow up to the 1473-IMIQ Study Phase 3
Completed NCT05060237 - Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp Phase 1
Recruiting NCT02737176 - Tobacco Cessation Intervention Study for Oral Diseases N/A
Completed NCT00110682 - Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Phase 4